The Relationship Between Scar Formation and ESD Depth in Therapy for Gastric Carcinoma

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Apr 5, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how deep doctors need to cut during a specific procedure called endoscopic submucosal dissection (ESD) to treat early-stage gastric cancer, which is cancer in the stomach that hasn't spread. The goal is to understand how the depth of these cuts affects the formation of scars afterwards. This research is important because it aims to provide better guidance on treating early gastric cancer, helping to improve patient outcomes.

To be eligible for this study, participants should be between 18 and 75 years old and have been diagnosed with early gastric cancer that meets certain criteria, such as having small lesions and no serious complications. Those who join the trial can expect to undergo the ESD procedure and will be monitored afterwards to see how well they heal and how their scars develop. It's essential to note that this study is currently recruiting participants, and there are specific health conditions that could prevent someone from taking part, such as advanced cancer or serious health issues that would make the procedure unsafe.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients older than 18 years old and younger than 75 years old.
• • Early gastric cancer (T1a stage) diagnosed by gastroscopy or ultrasonography, differentiated and no ulcer; or early gastric cancer (T1a stage), differentiated with ulcer, lesion diameter \<3cm; or early gastric cancer (T1a stage), undifferentiated and No ulcer, lesion diameter \<2cm.
• • Pathological diagnosis of gastric cancer.
• • No further treatment is required.
• • Patients diagnosed for the first time without other serious gastrointestinal diseases.
• Exclusion Criteria:
• • Those who did not comply with the test requirements, obviously violated this protocol, or switched to other protocols in the middle of treatment.
• • Advanced gastric cancer; or undifferentiated gastric cancer lesions \> 2 cm in diameter; or differentiated gastric cancer with ulcer lesions \> 3 cm in diameter.
• • Coagulation disorders.
• • Serious heart, liver, kidney and other diseases, can not tolerate ESD treatment.
• • Patients with gastric cancer complications such as gastrointestinal bleeding and perforation that need emergency treatment.
• • Patients with distant metastasis.
• • Patients with other tumors, patients with a history of malignant tumors (except early carcinoma in situ.
• • The patient himself requests to withdraw from the trial.
• • The researcher believes that the patient is not suitable to participate in this study.